AIM ImmunoTech Inc. 近日披露了其正在进行的二期临床试验的关键规划节点,该试验旨在评估其核心药物Ampligen与阿斯利康(AstraZeneca)的Durvalumab联合用于治疗转移性胰腺癌的疗效。公司明确了试验推进过程中的若干重要阶段,标志着该联合疗法研发进程的稳步推进。
AIM ImmunoTech Inc. 近日披露了其正在进行的二期临床试验的关键规划节点,该试验旨在评估其核心药物Ampligen与阿斯利康(AstraZeneca)的Durvalumab联合用于治疗转移性胰腺癌的疗效。公司明确了试验推进过程中的若干重要阶段,标志着该联合疗法研发进程的稳步推进。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.